Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment

Immunity 2026 Open access

Read full text
Authors: Vivien I. Maltez, Charu Arora, Kyle P. Gribbin, Breanna Caruso, Margaret Haerr, Rina Sor, Qiaoshi Lian, Katie E. Blise, Shamilene Sivagnanam, Rosalie C. Sears, Lisa M. Coussens, Robert H. Vonderheide
+2 more Ronald N. Germain, Katelyn T. Byrne
DOI: 10.1016/j.immuni.2026.03.011
Cited by: 2
References: 90

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research Immunotherapy and Immune Responses

Publication details

Journal / source
Immunity
Publisher
Elsevier BV
Volume
59
Issue
4
Pages
1058–1074.e7
Publication date
1 April 2026
Language
EN